BETHESDA, Md-The National Cancer Institute is urging the Federal Trade Commission (FTC) to replace its current cigarette testing protocol with one that provides the full range of tar, nicotine and carbon monoxide yields in individual cigarette brands.
BETHESDA, MdThe National Cancer Institute is urging the Federal Trade Commission (FTC) to replace its current cigarette testing protocol with one that provides the full range of tar, nicotine and carbon monoxide yields in individual cigarette brands.
The NCI's newest monograph in its series on Smoking and Tobacco Control contains the findings and recommendations of an expert committee that addressed the need for changes in the FTC's cigarette-testing method. The committee also recommended the following:
A public education campaign must accompany the new testing approach to make smokers aware that an individual's exposure depends on how a cigarette is smoked and that the benefits of switching to lower-yield cigarettes are small compared to quitting.
Single copies of the monograph, "The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of US CigarettesReport of the NCI Expert Committee," are available from NCI at 1-800-422-6237.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.